الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
Serum ferritin has often been used as a surrogate marker for systemic iron stores, however, it may be elevated in cases even without excess iron stores, such as during inflammation. Elevated levels of serum ferritin have been thought to be an adverse prognostic factor in patients with several solid tumors and in those with hematologic malignancies.
Several studies have suggested that elevated levels of serum ferritin were associated with worse outcomes in malignant lymphoma. The purpose of this study was to detect the correlation between elevated levels of serum ferritin and the outcomes of patients with malignant lymphoma.
A total of 100 newly diagnosed patients with malignant lymphoma, presented to Clinical oncology department, Menoufia University, were included in this study. Twenty-three cases of them were diagnosed as Hodgkin lymphoma and 77 cases as Non Hodgkin lymphoma. Median age at diagnosis was 53.6 years (ranging from 13–80) in NHL and 40.78 years (ranging from 18-68) in HL.
We have found that elevated serum ferritin level was significantly associated with features suggestive of aggressive disease as: advanced stage disease, poor PS, elevated LDH and elevated β2 microglobulin in patients with NHL, while it was associated with advanced stage and elevated β2 microglobulin in HL group.
However, hyperferritinemia was found not to be associated to response to treatment or survival in both NHL and HL groups.
In univariate analysis, there was significant association between high/intermediate risk IPI, LDH and time to treatment failure in NHL group (P value= 0.002, 0.005 respectively), however, multivariate analysis revealed that only high/ high-intermediate IPI was significantly associated with TTF in patients with NHL.
Regarding OS in NHL group, univariate analysis showed that there was significant association between high risk IPI, LDH, advanced stage and B2 microglobulin, and OS (P value = 0.009, <0.001, 0.023 and 0.04 respectively), although multivariate analysis showed that elevated LDH only was significantly associated with OS.
There was no significant association between age, gender, high risk IPS, ESR, advanced stage, Hb and TLC and TTF or OS in patients with HL, which might be explained by small number of patients with HL included in the study.
Elevated levels of serum ferritin (≥ 300 ng/mL in males and ≥ 200 ng/L in females) was found to have no significant association with the therapeutic and the survival outcomes of patients in both NHL and HL.
We concluded that serum ferritin might be associated with features suggesting aggressive disease in patients with malignant lymphoma. However, the correlation between elevated ferritin level and the outcome can’t be detected.